Provided by Tiger Trade Technology Pte. Ltd.

Belite Bio, Inc.

176.08
-7.0800-3.87%
Volume:72.37K
Turnover:12.94M
Market Cap:7.09B
PE:-64.30
High:181.23
Open:180.27
Low:174.30
Close:183.16
52wk High:200.00
52wk Low:64.80
Shares:40.27M
Float Shares:19.38M
Volume Ratio:0.31
T/O Rate:0.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7382
EPS(LYR):-2.3141
ROE:-22.10%
ROA:-15.65%
PB:9.13
PE(LYR):-76.09

Loading ...

Belite Bio CFO Chuang Hao-Yuan Sells USD 8.85 Million in Common Shares

Reuters
·
Yesterday

Mizuho Raises Price Target on Belite Bio to $234 From $220, Keeps Outperform Rating

MT Newswires Live
·
Sep 09

U.S. Research Roundup-Argan, Mastec, Oracle

Reuters
·
Sep 09

Belite Bio Price Target Raised to $245.00/Share from $214.00 by HC Wainwright & Co.

Dow Jones
·
Sep 08

Belite Bio, Inc : H.c. Wainwright Raises Target Price to $245 from $214

THOMSON REUTERS
·
Sep 08

Belite Bio submits NDA to MHLW in Japan for tinlarebant in STGD1

TIPRANKS
·
Sep 08

Belite Bio Files Japan NDA for Tinlarebant Under Sakigake Designation for Stargardt Disease Type 1

Reuters
·
Sep 08

Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan Under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1

THOMSON REUTERS
·
Sep 08

Belite Bio, - FDA Accepts Nda with Priority Review for Tinlarebant; Pdufa Target Date Feb 12, 2027

THOMSON REUTERS
·
Sep 08

Mizuho Securities Sticks to Their Buy Rating for Belite Bio, Inc. ADR (BLTE)

TIPRANKS
·
Sep 06

Belite Bio Shares Rise After Canaccord Initiates Coverage With Buy Rating

MT Newswires Live
·
Sep 05

Belite Bio's Tinlarebant Revenue Estimates Have Multiple Drivers of Upside, Mizuho Says

MT Newswires Live
·
Sep 04

Belite Bio, Inc : Canaccord Genuity Initiates Coverage with Buy Rating; Target Price $303

THOMSON REUTERS
·
Sep 04

Belite Bio Initiated at Buy by Canaccord Genuity

Dow Jones
·
Sep 04

Canaccord Genuity Initiates Belite Bio at Buy With $303 Price Target

MT Newswires Live
·
Sep 04

Belite Bio initiated with a Buy at Canaccord

TIPRANKS
·
Sep 04

U.S. Research Roundup-Ciena Corp, Docusign, Snowflake

Reuters
·
Sep 04

Belite Bio to Participate in Four Upcoming Investor Conferences

GlobeNewswire
·
Sep 01

Belite Bio to Host Virtual Commercial Day on Tinlarebant Opportunity in Stargardt Disease Type 1

Reuters
·
Aug 25

Belite Bio to Host Virtual Commercial Day on September 2, 2026

GlobeNewswire
·
Aug 25